NRx Pharmaceuticals, Inc. NRXP
Set alert
At close · Nov 2
After hours · Nov 2, 5:16 PM ET
- YTD
- -19.93%
- 1 year
- -30.00%
- Open
- 2.32
- Prev close
- 2.27
- Mkt cap
- 93.95M
- Vol
- 2.44M
- Avg vol
- 1.09M
- EPS
- -0.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.14
- High
- 2.44
- Forward P/E
- -1.12
- Beta
- 1.27
- Short ratio
- 4.80
- Inst. own
- 6.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.28
- 200-d avg
- 2.53
- 1y target
- 31.67
5D chart
Signals (77)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 3:30 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 3:25 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 3:05 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 2:45 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 2:30 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 2:15 PM | 3 hours ago |
| MACD: Buy Signal | Nov 2, 2:15 PM | 3 hours ago |
| MACD: Sell Signal | Nov 2, 1:10 PM | 4 hours ago |
| SMA: Bullish | Nov 2, 11:55 AM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 11:55 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 10:35 AM | 6 hours ago |
| SMA: Bullish | Nov 2, 10:30 AM | 6 hours ago |
| SMA: Bearish | Nov 2, 10:10 AM | 7 hours ago |
| MACD: Sell Signal | Nov 2, 10:10 AM | 7 hours ago |
| SMA: Bearish | Nov 2, 10:05 AM | 7 hours ago |
| RSI: Overbought | Nov 2, 9:40 AM | 7 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 7 hours ago |
| MACD: Buy Signal | Nov 2, 9:30 AM | 7 hours ago |
| SMA: Bearish | Oct 30, 3:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 3 days ago |
| RSI: Oversold | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:20 PM | 4 days ago |
| RSI: Oversold | Oct 29, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:10 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 2:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| RSI: Overbought | Oct 27, 12:05 PM | 6 days ago |
News
8 hours ago benzinga.com
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
-
12 hours ago benzinga.com
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.
3 days ago seekingalpha.com
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
3 days ago marketbeat.com
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
NRx Pharmaceuticals NASDAQ: NRXP said the U.S. Food and Drug Administration approved its abbreviated new drug application for preservative-free ketamine injection, marking the company's first…
3 days ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
-
3 days ago benzinga.com
NRx Pharmaceuticals Receives FDA Approval Of Its Abbreviated New Drug Application For Preservative-Free Ketamine
The approval comes ahead of the FDA-announced November 10, approval goal date.Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride…
3 days ago globenewswire.com
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
WILMINGTON, Del., Oct. 30, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target…
3 days ago benzinga.com
Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Civeo shares surged 19.9% after earnings beat estimates and FY2026 sales guidance rose; other premarket movers included SLGB, HUBC and ATEC.
3 days ago benzinga.com
NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge?
NRx Pharmaceuticals shares jump 26.69% after hours as investors await details of a regulatory milestone for its ketamine program.
4 days ago globenewswire.com
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Company to issue press release before market open; conference call to follow at 8:30 a.m. ET Company to issue press release before market open; conference call to follow at 8:30 a.m. ET
-
2 weeks ago benzinga.com
NRx Pharmaceuticals Completes Three Process Validation Lots Of Preservative Free Ketamine Produced Under Commercial Conditions In Anticipation Of Nov. 10 Generic Drug User Fee Amendments Goal Date
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central
2 weeks ago globenewswire.com
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its…
-
2 weeks ago benzinga.com
NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the
2 weeks ago globenewswire.com
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.” NRx was requested to prepare and submit labels with the proprietary name currently under review by…
-
1 month ago benzinga.com
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $49 to $50.
-
1 month ago benzinga.com
NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency
DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are…
1 month ago globenewswire.com
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are…
1 month ago defenseworld.net
Head-To-Head Analysis: BeOne Medicines (NASDAQ:ONC) versus NRx Pharmaceuticals (NASDAQ:NRXP)
NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) and BeOne Medicines (NASDAQ: ONC - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two…
-
1 month ago benzinga.com
FDA Reclassifies NRx Pharmaceuticals' Ketamine ANDA Amendment To Minor, Setting New Goal Date For November 10, 2026
Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic…
1 month ago globenewswire.com
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today…
-
1 month ago benzinga.com
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $10 price target.
1 month ago seekingalpha.com
NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry
KETAFREE could turn NRXP's ketamine opportunity into a commercial business, provided FDA approval leads to a successful launch. NRXP's HOPE gives them clinical infrastructure, even though it still…
-
1 month ago benzinga.com
NRx Pharma’s GeNeuro Announces Award Of European Patent Entitled Anti HERV K Envelope Antibody And Uses Thereof
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the "dark genome" of all people.K Env…
1 month ago globenewswire.com
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env…
-
1 month ago benzinga.com
NRx Pharmaceuticals’ HOPE Therapeutics To Deploy Zeta Surgical's Newly FDA-Cleared Zeta TMS Robotic System, With Clinical Staff Now In Training Ahead Of Deployment In Florida
HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completing orientation and training at Zeta Surgical's…
1 month ago globenewswire.com
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today…
1 month ago globenewswire.com
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
2 months ago seekingalpha.com
NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
2 months ago benzinga.com
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. This content is powered by Benzinga APIs. For…
-
2 months ago benzinga.com
NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of…
2 months ago globenewswire.com
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company's ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining…
2 months ago zacks.com
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago.
2 months ago seekingalpha.com
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript
2 months ago marketbeat.com
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
NRx Pharmaceuticals NASDAQ: NRXP said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with…
-
2 months ago benzinga.com
NRx Pharmaceuticals To Host Conference Call And Q&A Session On August 10 To Discuss FDA's Completion Of First-Cycle Review Of Its ANDA For Preservative-Free Ketamine
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on
2 months ago globenewswire.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host…
-
2 months ago benzinga.com
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10
BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.
-
2 months ago benzinga.com
NRx Pharmaceuticals Announces FDA Found No Major Deficiencies In Its First-Cycle Review Of ANDA For Its Preservative-Free Ketamine
No major deficiencies related to the drug product, ingredients, proposed labeling, Chemistry, Manufacturing and Controls, or other drug-related review matters. No new clinical, safety, efficacy, or…
2 months ago globenewswire.com
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters. Remaining item relates to manufacturer…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock…
-
4 months ago benzinga.com
NRx Pharmaceuticals Issues Statement In Response To Kadima Allegations, Citing Arbitration Over Non‑Acquisition By HOPE Therapeutics
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx" or the "Company") today issued the following statement in response to recent public claims made by Kadima Neuropsychiatry Institute
-
4 months ago benzinga.com
NRx Pharma’s HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient careAI-powered,…
-
4 months ago benzinga.com
NRx Pharma Announces FDA Approval Of Intermediate Population Expanded Access Protocol For Use Of NRX-101, Fixed Dose Combination Of DCS And Lurasidone For Augmentation Of Accelerated TMS
D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies.NRx…
-
5 months ago benzinga.com
NRx Pharmaceuticals Prices $20M Public Offering Of 5,714,286 Shares Of Common Stock At A Price Of $3.50/Share To Fund Working Capital And Growth Plans
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering (the…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
5 months ago benzinga.com
Why Tetra Technologies Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket
Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100M stock offering. XOS, Wellchange, and J-Star are top gainers while Jianzhi, NRx, and Volato are…
5 months ago benzinga.com
NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's Why
NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise capital for growth and operations.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
5 months ago benzinga.com
NRx Pharmaceuticals Announces Proposed Underwritten Public Offering Of Common Stock; No Terms Disclosed
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its common stock, par…